Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to reverse liver damage from heavy drinking

NCT ID NCT07009860

Disease control Sponsor: Altimmune, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study tests a weekly injection called pemvidutide in 100 adults with alcohol-related liver disease. Participants are overweight or obese and have a history of heavy drinking. The goal is to see if the drug can reduce liver stiffness and scarring over 24 to 48 weeks compared to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

121 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female ages 18 to 75 years, inclusive 2. Overweight or obesity, defined as BMI ≥ 25 kg/m2 3. History of alcohol misuse for the prior 3 years, with an alcohol intake ≥ 50 grams per day for males and ≥ 40 grams per day for females on average in the past year 4. Evidence of recent alcohol use, defined as PEth level ≥ 35 ng/mL at screening 5. Liver stiffness of 10.0-24.9 kPa by VCTE, inclusive Exclusion Criteria: 1. Presence of clinically significant alcohol withdrawal symptoms, defined as CIWA-Ar score ≥ 10 at screening and/or prior to randomization 2. History of hospitalization for alcohol withdrawal within the past year 3. History of seizures related to alcohol within the past year 4. History and/or current diagnosis of schizophrenia, bipolar disorder, psychotic disorder, or another severe psychiatric disorder, unless documented as well-controlled by the Investigator for at least 6 months prior to screening and cleared by the Medical Monitor 5. Attempted suicide and/or serious suicidal intention or plan in the past 10 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol liver disease Alcohol-associated liver disease

Contacts and locations

Locations

  • Altimmune Clinical Study Site

    Peoria, Arizona, 85381, United States

  • Altimmune Clinical Study Site

    Tucson, Arizona, 85712, United States

  • Altimmune Clinical Study Site

    North Little Rock, Arkansas, 72117, United States

  • Altimmune Clinical Study Site

    Fresno, California, 93720, United States

  • Altimmune Clinical Study Site

    La Jolla, California, 92037, United States

  • Altimmune Clinical Study Site

    Pasadena, California, 91105, United States

  • Altimmune Clinical Study Site

    Bradenton, Florida, 34201, United States

  • Altimmune Clinical Study Site

    Doral, Florida, 33122, United States

  • Altimmune Clinical Study Site

    Fort Myers, Florida, 33192, United States

  • Altimmune Clinical Study Site

    Miami, Florida, 33125, United States

  • Altimmune Clinical Study Site

    Miami, Florida, 33165, United States

  • Altimmune Clinical Study Site

    Miami Lakes, Florida, 33122, United States

  • Altimmune Clinical Study Site

    Naples, Florida, 34102, United States

  • Altimmune Clinical Study Site

    Orlando, Florida, 32803, United States

  • Altimmune Clinical Study Site

    Atlanta, Georgia, 30309, United States

  • Altimmune Clinical Study Site

    Indianapolis, Indiana, 46202, United States

  • Altimmune Clinical Study Site

    Louisville, Kentucky, 40202, United States

  • Altimmune Clinical Study Site

    Bastrop, Louisiana, 71220, United States

  • Altimmune Clinical Study Site

    Marrero, Louisiana, 70072, United States

  • Altimmune Clinical Study Site

    West Monroe, Louisiana, 71291, United States

  • Altimmune Clinical Study Site

    St Louis, Missouri, 63123, United States

  • Altimmune Clinical Study Site

    Las Vegas, Nevada, 89106, United States

  • Altimmune Clinical Study Site

    Manhasset, New York, 11030, United States

  • Altimmune Clinical Study Site

    New York, New York, 10032, United States

  • Altimmune Clinical Study Site

    Syracuse, New York, 13210, United States

  • Altimmune Clinical Study Site

    Wilmington, North Carolina, 28403, United States

  • Altimmune Clinical Study Site

    Westlake, Ohio, 44145, United States

  • Altimmune Clinical Study Site

    Brownsville, Texas, 78520, United States

  • Altimmune Clinical Study Site

    Dallas, Texas, 75390, United States

  • Altimmune Clinical Study Site

    Edinburg, Texas, 78539, United States

  • Altimmune Clinical Study Site

    Houston, Texas, 77030, United States

  • Altimmune Clinical Study Site

    Houston, Texas, 77079, United States

  • Altimmune Clinical Study Site

    San Antonio, Texas, 78215, United States

  • Altimmune Clinical Study Site

    San Antonio, Texas, 78251, United States

  • Altimmune Clinical Study Site

    Waco, Texas, 76710, United States

  • Altimmune Clinical Study Site

    Seattle, Washington, 98105, United States

  • Altimmune Clinical Study Site

    San Juan, 00927, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.